Publicaciones en colaboración con investigadores/as de Pontifícia Universidade Católica do Rio Grande do Sul (37)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  2. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

  3. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038

2023

  1. An international comparative analysis and roadmap to sustainable biosimilar markets

    Frontiers in Pharmacology, Vol. 14

  2. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

    Mayo Clinic Proceedings

  3. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification

    Kidney International, Vol. 104, Núm. 6, pp. 1092-1102

  4. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

  5. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

2022

  1. Code of practice needed for samples donated by trial participants

    The Lancet Oncology

  2. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

  3. Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries

    Frontiers in Pediatrics, Vol. 10

  4. Latin American Consensus on the Management of Sepsis in Children: Sociedad Latinoamericana de Cuidados Intensivos Pediátricos [Latin American Pediatric Intensive Care Society] (SLACIP) Task Force: Executive Summary

    Journal of Intensive Care Medicine, Vol. 37, Núm. 6, pp. 753-763

2021

  1. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

    Clinical Breast Cancer, Vol. 21, Núm. 1, pp. 80-91.e7

2020

  1. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72

  2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  3. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

  4. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213

  5. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    European Journal of Cancer, Vol. 138, pp. 202-211

2019

  1. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)

    BMC Cancer

  2. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial

    Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574